Tessera Therapeutics
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
Tessera Therapeutics is pioneering Gene Writing™—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Our mission is to cure disease by writing in the code of life.
Company HQ City:
Somerville
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
In vivo gene editing therapy for alpha-1 antitrypsin deficiency (AATD)
CEO
Michael Severino
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
2026
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}